Difference between revisions of "Team:Shanghai Metro Utd/Engineering"

(Prototype team page)
 
Line 1: Line 1:
−
{{IGEM_TopBar}}
+
<html lang="en">
−
{{Shanghai_Metro_Utd}}
+
−
<html>
+
  
 +
<head>
 +
    <meta charset="UTF-8">
 +
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
 +
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
 +
    <title>Shanghai_Metro_Utd</title>
 +
    <link rel="stylesheet"
 +
        href="https://2021.igem.org/wiki/index.php?title=Template:Shanghai_Metro_Utd/Main_CSS&action=raw&ctype=text/css" />
  
−
<div class="column full_size judges-will-not-evaluate">
+
</head>
−
<h3>★  ALERT! </h3>
+
−
<p>This page is used by the judges to evaluate your team for the <a href="https://2021.igem.org/Judging/Medals">medal criterion</a> or <a href="https://2021.igem.org/Judging/Awards"> award listed below</a>. </p>
+
−
<p> Delete this box in order to be evaluated for this medal criterion and/or award. See more information at <a href="https://2021.igem.org/Judging/Pages_for_Awards"> Instructions for Pages for awards</a>.</p>
+
−
</div>
+
−
 
+
−
 
+
−
<div class="clear"></div>
+
−
 
+
−
 
+
−
<div class="column full_size">
+
−
<h1>Engineering Success</h1>
+
−
<h3> Silver Medal Criterion #1</h3>
+
−
 
+
−
<p>Demonstrate engineering success in a part of your project by going through at least one iteration of the engineering design cycle. This achievement should be distinct from your Contribution for Bronze.
+
−
<br><br>
+
−
Please see the <a href="https://2021.igem.org/Judging/Medals">2021 Medals Page</a> for more information.
+
−
</p>
+
−
 
+
−
 
+
−
<p>If you plan to show engineering success by creating a new Part that has been shown to work as expected, you must document your contribution on the Part's Main Page on the <a href="http://parts.igem.org/Main_Page">Registry</a> for your team to be eligible for this criteria.</p>
+
−
 
+
−
</div>
+
  
 +
<body>
 +
    <nav class="head-nav clearfix">
 +
        <div class="top-block"></div>
 +
        <div class="top-nav-bar">
 +
            <ul class="clearfix">
 +
                <span class="small-logo"></span>
 +
                <li>
 +
                    <a href="https://2021.igem.org/Team:Shanghai_Metro_Utd">Home</a>
 +
                </li>
 +
                <li>
 +
                    <a href="">Project</a>
 +
                    <div class="sub-nav">
 +
                        <ul>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Description"
 +
                                    class="sub-nav-74">Description</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Experiments"
 +
                                    class="sub-nav-74">Experiments</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Results"
 +
                                    class="sub-nav-74">Results</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Proof_Of_Concept"
 +
                                    class="sub-nav-52">Proof Of
 +
                                    Concept</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Notebook"
 +
                                    class="sub-nav-52">Notebook</a>
 +
                            </li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Safety">Safety</a></li>
 +
                        </ul>
 +
                    </div>
 +
                </li>
 +
                <li class="active">
 +
                    <a href="">Parts</a>
 +
                    <div class="sub-nav">
 +
                        <ul>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Collection"
 +
                                    class="sub-nav-74">Parts
 +
                                    Collection</a></li>
 +
                            <li class="current-sub-nav"><a href="#" class="sub-nav-74">Engineering</a></li>
 +
                        </ul>
 +
                    </div>
 +
                </li>
 +
                <li>
 +
                    <a href="">Human Practices</a>
 +
                    <div class="sub-nav">
 +
                        <ul>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Human_Practices"
 +
                                    class="sub-nav-74">Integrated
 +
                                    Human Practice</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Communication"
 +
                                    class="sub-nav-74">Communication</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Fundraising"
 +
                                    class="sub-nav-74">Fundraising</a></li>
 +
                        </ul>
 +
                    </div>
 +
                </li>
 +
                <li>
 +
                    <a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Implementation">Implementation</a>
 +
                </li>
 +
                <li>
 +
                    <a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Entrepreneurship">Entrepreneurship</a>
 +
                </li>
 +
                <li>
 +
                    <a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Model">Model</a>
 +
                </li>
 +
                <li>
 +
                    <a href="">Team</a>
 +
                    <div class="sub-nav">
 +
                        <ul>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Members" class="sub-nav-74">Team
 +
                                    Members</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Attributions"
 +
                                    class="sub-nav-74">Attributions</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro_Utd/Collaborations"
 +
                                    class="sub-nav-74">Collaborations</a></li>
 +
                        </ul>
 +
                    </div>
 +
                </li>
 +
            </ul>
 +
        </div>
 +
    </nav>
 +
    <div class="sub-content">
 +
        <div class="sub-title">Engineering</div>
 +
        <div class="article-title">Background </div>
 +
        <div class="article-content">Parkinson’s disease affects more than 4 million people worldwide. In the United
 +
            States, Parkinson’s disease occurs in approximately 13 per 100,000 people, and about 60,000 new cases are
 +
            identified each year. With more people living longer than before, the number of people who can get this
 +
            disease is expected to increase in the coming decades. Parkinson's disease is highly senile, and this
 +
            disease has seriously threatened the health of elderly people. This disease leads to a gradual loss of
 +
            physical motor function, lethargy, inconvenience, and slowness of movement. At the same time, patients will
 +
            also have different degrees of depression and anxiety symptoms. There is an urgent need for medical
 +
            treatments that are both effective and affordable for the majority of the aged population. However, the
 +
            current medication cannot satisfy the demand for most aged population, since it only relieves the symptom
 +
            and maintains the life quality of the patients to some extent. </div>
 +
        <div class="article-title">Design </div>
 +
        <div class="article-content">During our process of reading massive public literature on the matter, we came
 +
            across a relatively new target, angiogenin (ANG) protein, a secreted ribonuclease. According to the
 +
            literatures, angiogenin has been recognized to play important roles in various physiological and
 +
            pathological processes, especially in neurodegenerative diseases. The loss-of-function mutation of the ANG
 +
            gene is likely to be an important cause of certain nervous system diseases such as Parkinson’s disease.
 +
            Therefore, we realized that the delivery of active angiogenin protein could reduce neurodegeneration and
 +
            could possibly be used as a clinical treatment once we correctly inject the protein. </div>
 +
        <div class="article-content">In our project, we aim to create a recombinant bacteria that can secret functional
 +
            ANG protein, which could possibly serve as an in vitro method to massive produce ANG for clinical use.</div>
 +
        <div class="article-title">Build </div>
 +
        <div class="article-content">pET-28a-rANG which produces ANG protein is shown in Figure 1.</div>
 +
        <div class="img-wrap no-margin">
 +
            <img src="https://static.igem.org/mediawiki/2021/0/05/T--Shanghai_Metro_Utd--engineering01.jpg" alt="">
 +
            <span>Figure 1. Schematic map of pET-28a-rANG plasmid and its construction.</span>
 +
        </div>
 +
        <div class="article-title">Test </div>
 +
        <div class="article-content">We have obtained Freeze-dried powder of the ANG protein produced by our engineered
 +
            Escherichia coli (Figure 2). </div>
 +
        <div class="img-wrap no-margin">
 +
            <img src="https://static.igem.org/mediawiki/2021/f/f9/T--Shanghai_Metro_Utd--engineering02.jpg" alt="" />
 +
            <span>Figure 2. Freeze-dried powder of the ANG protein.</span>
 +
        </div>
 +
        <div class="article-content">The activity of recombinant ANG protein was determined by the RNA degradation
 +
            assay. The result indicated that ANG protein possesses ribonuclease activity as we expected.</div>
 +
        <div class="img-wrap no-margin">
 +
            <img src="https://static.igem.org/mediawiki/2021/1/1b/T--Shanghai_Metro_Utd--engineering03.jpg" alt="" />
 +
            <span>Figure 3. RNA degradation by ANG.</span>
 +
        </div>
 +
    </div>
 +
    <footer class="footer">
 +
        <section class="footer-wrap">
 +
            <p class="margin-bottom-14">Email us at:<i
 +
                    style="color:#0546ff; font-style: normal;">ashleyyang48@gmail.com;alexlin711@gmail.com</i></p>
 +
            <p>Follow us on Wechat: <i style="color:#650000; font-size: 18px;">血管马力Bloody
 +
                    Marry</i></p>
 +
        </section>
 +
    </footer>
 +
</body>
 +
<script>
 +
    let liTags = document.querySelectorAll(".top-nav-bar > ul > li");
 +
    let len = liTags.length;
 +
    for (let i = 0; i < len; i++) {
 +
        liTags[i].onclick = function (e) {
 +
            //先移除所有的点击样式
 +
            for (let j = 0; j < len; j++) {
 +
                liTags[j].classList.remove("active");
 +
            }
 +
            //再添加点击样式
 +
            let li = e.currentTarget;
 +
            li.classList.add("active");
 +
        }
 +
    }
 +
</script>
  
 
</html>
 
</html>

Revision as of 16:00, 15 October 2021

Shanghai_Metro_Utd

Engineering
Background
Parkinson’s disease affects more than 4 million people worldwide. In the United States, Parkinson’s disease occurs in approximately 13 per 100,000 people, and about 60,000 new cases are identified each year. With more people living longer than before, the number of people who can get this disease is expected to increase in the coming decades. Parkinson's disease is highly senile, and this disease has seriously threatened the health of elderly people. This disease leads to a gradual loss of physical motor function, lethargy, inconvenience, and slowness of movement. At the same time, patients will also have different degrees of depression and anxiety symptoms. There is an urgent need for medical treatments that are both effective and affordable for the majority of the aged population. However, the current medication cannot satisfy the demand for most aged population, since it only relieves the symptom and maintains the life quality of the patients to some extent.
Design
During our process of reading massive public literature on the matter, we came across a relatively new target, angiogenin (ANG) protein, a secreted ribonuclease. According to the literatures, angiogenin has been recognized to play important roles in various physiological and pathological processes, especially in neurodegenerative diseases. The loss-of-function mutation of the ANG gene is likely to be an important cause of certain nervous system diseases such as Parkinson’s disease. Therefore, we realized that the delivery of active angiogenin protein could reduce neurodegeneration and could possibly be used as a clinical treatment once we correctly inject the protein.
In our project, we aim to create a recombinant bacteria that can secret functional ANG protein, which could possibly serve as an in vitro method to massive produce ANG for clinical use.
Build
pET-28a-rANG which produces ANG protein is shown in Figure 1.
Figure 1. Schematic map of pET-28a-rANG plasmid and its construction.
Test
We have obtained Freeze-dried powder of the ANG protein produced by our engineered Escherichia coli (Figure 2).
Figure 2. Freeze-dried powder of the ANG protein.
The activity of recombinant ANG protein was determined by the RNA degradation assay. The result indicated that ANG protein possesses ribonuclease activity as we expected.
Figure 3. RNA degradation by ANG.

Email us at:ashleyyang48@gmail.com;alexlin711@gmail.com

Follow us on Wechat: 血管马力Bloody Marry